Log in

NASDAQ:ALPN - Alpine Immune Sciences Stock Price, Forecast & News

$2.88
+0.38 (+15.20 %)
(As of 04/1/2020 06:00 AM ET)
Today's Range
$2.60
Now: $2.88
$3.00
50-Day Range
$2.20
MA: $2.90
$3.39
52-Week Range
$2.05
Now: $2.88
$8.24
Volume27,009 shs
Average Volume20,792 shs
Market Capitalization$53.54 million
P/E RatioN/A
Dividend YieldN/A
Beta1.58
Alpine Immune Sciences, Inc. focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202, a programmed cell death protein ligand 1 (PD-L1)/cytotoxic T-lymphocyte associated protein 4 (CTLA-4) antagonist with PD-L1 dependent CD28 costimulation for the treatment of cancer. The company has a collaboration and licensing agreement with the Kite Pharma, Inc. for discovering and developing protein-based immunotherapies targeting the immune synapse to treat cancer. Alpine Immune Sciences, Inc. is headquartered in Seattle, Washington.
Read More
Alpine Immune Sciences logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ALPN
CUSIPN/A
Phone206-788-4545

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.74 million
Book Value$3.22 per share

Profitability

Net Income$-36,490,000.00

Miscellaneous

Employees48
Market Cap$53.54 million
Next Earnings Date5/14/2020 (Estimated)
OptionableNot Optionable

Receive ALPN News and Ratings via Email

Sign-up to receive the latest news and ratings for ALPN and its competitors with MarketBeat's FREE daily newsletter.


Alpine Immune Sciences (NASDAQ:ALPN) Frequently Asked Questions

How has Alpine Immune Sciences' stock been impacted by COVID-19 (Coronavirus)?

Alpine Immune Sciences' stock was trading at $2.91 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ALPN shares have decreased by 1.0% and is now trading at $2.88. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Alpine Immune Sciences?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alpine Immune Sciences in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Alpine Immune Sciences.

When is Alpine Immune Sciences' next earnings date?

Alpine Immune Sciences is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for Alpine Immune Sciences.

How were Alpine Immune Sciences' earnings last quarter?

Alpine Immune Sciences Inc (NASDAQ:ALPN) posted its quarterly earnings data on Monday, March, 30th. The biotechnology company reported ($0.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.55) by $0.22. The biotechnology company earned $0.88 million during the quarter, compared to analyst estimates of $0.28 million. View Alpine Immune Sciences' earnings history.

What price target have analysts set for ALPN?

1 equities research analysts have issued 12-month price targets for Alpine Immune Sciences' stock. Their forecasts range from $8.00 to $8.00. On average, they anticipate Alpine Immune Sciences' share price to reach $8.00 in the next year. This suggests a possible upside of 177.8% from the stock's current price. View analysts' price targets for Alpine Immune Sciences.

Has Alpine Immune Sciences been receiving favorable news coverage?

Headlines about ALPN stock have been trending very negative on Wednesday, according to InfoTrie. The research group identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Alpine Immune Sciences earned a media sentiment score of -3.0 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 4.0 out of 10, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near future. View the latest news aboutAlpine Immune Sciences.

Are investors shorting Alpine Immune Sciences?

Alpine Immune Sciences saw a decline in short interest in the month of March. As of March 13th, there was short interest totaling 4,400 shares, a decline of 56.0% from the February 27th total of 10,000 shares. Based on an average daily trading volume, of 13,600 shares, the short-interest ratio is currently 0.3 days. Currently, 0.1% of the shares of the stock are sold short. View Alpine Immune Sciences' Current Options Chain.

Who are some of Alpine Immune Sciences' key competitors?

What other stocks do shareholders of Alpine Immune Sciences own?

Who are Alpine Immune Sciences' key executives?

Alpine Immune Sciences' management team includes the following people:
  • Dr. Mitchell H. Gold, Exec. Chairman & CEO (Age 51)
  • Dr. Stanford Peng, Pres and Head of R&D (Age 48)
  • Mr. Paul Rickey, Sr. VP, CFO & Corp. Sec. (Age 40)
  • Dr. Kristine Swiderek Ph.D., Sr. VP of Research

What is Alpine Immune Sciences' stock symbol?

Alpine Immune Sciences trades on the NASDAQ under the ticker symbol "ALPN."

How do I buy shares of Alpine Immune Sciences?

Shares of ALPN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Alpine Immune Sciences' stock price today?

One share of ALPN stock can currently be purchased for approximately $2.88.

How big of a company is Alpine Immune Sciences?

Alpine Immune Sciences has a market capitalization of $53.54 million and generates $1.74 million in revenue each year. The biotechnology company earns $-36,490,000.00 in net income (profit) each year or ($2.28) on an earnings per share basis. Alpine Immune Sciences employs 48 workers across the globe. View additional information about Alpine Immune Sciences.

What is Alpine Immune Sciences' official website?

The official website for Alpine Immune Sciences is http://www.alpineimmunesciences.com/.

How can I contact Alpine Immune Sciences?

Alpine Immune Sciences' mailing address is 201 Elliott Avenue West Suite 230, Seattle WA, 98119. The biotechnology company can be reached via phone at 206-788-4545 or via email at [email protected]


MarketBeat Community Rating for Alpine Immune Sciences (NASDAQ ALPN)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  330 (Vote Outperform)
Underperform Votes:  355 (Vote Underperform)
Total Votes:  685
MarketBeat's community ratings are surveys of what our community members think about Alpine Immune Sciences and other stocks. Vote "Outperform" if you believe ALPN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALPN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/1/2020 by MarketBeat.com Staff

Featured Article: 52- Week Highs

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel